Adiponectin serum level in chronic hepatitis C infection and therapeutic profile

World Journal of Hepatology

Volumn 7, Issue 1, 2015, Pages 44-52

  Peta, Valentina ^a   Torti, Carlo ^a   Milic, Natasa ^b   Focà, Alfredo ^a   Abenavoli, Ludovico ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Adiponectin; Hepatitis C virus; Hepatitis C virus core protein; Insulin resistance; Metabolism

Indexed keywords

EID: 84920911233     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i1.44     Document Type: Article

References (81)

1. Björnsson E, Angulo P. Hepatitis C and steatosis. Arch Med Res 2007; 38: 621-627, PMID: 17613353 DOI: 10.1016/j. arcmed.2006.09.001
2. Torti C, Zazzi M, Abenavoli L, Trapasso F, Cesario F, Corigliano D, Cosco L, Costa C, Curia RL, De Rosa M, Foti G, Giraldi C, Leone R, Liberto MC, Lucchino D, Marascio N, Masciari R, Matera G, Pisani V, Serrao N, Surace L, Zicca E, Castelli F, Ciccozzi M, Puoti M, Focà A. Future research and collaboration: the "SINERGIE" project on HCV (South Italian Network for Rational Guidelines and International Epidemiology). BMC Infect Dis 2012; 12 Suppl 2: S9, PMID: 23173812 DOI: 10.1186/1471-2334-12-S2-S9
3. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816, PMID: 11584380
4. Abenavoli L, Rouabhia S. Type 2 diabetes mellitus in chronic hepatitis C virus infection: risk factor or consequence? Expert Rev Gastroenterol Hepatol 2013; 7: 295-297, PMID: 23639086 DOI: 10.1586/egh.13.13
5. Abenavoli L, Almasio PL. Chronic hepatitis C infection and insulin resistance: two best friends. Expert Rev Anti Infect Ther 2011; 9: 555-558, PMID: 21819320 DOI: 10.1586/eri.11.72
6. Khan M, Jahan S, Khaliq S, Ijaz B, Ahmad W, Samreen B, Hassan S. Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis. Arch Virol 2010; 155: 1735-1753, PMID: 20842391 DOI: 10.1007/s00705-010-0797-7
7. Roingeard P. Hepatitis C virus diversity and hepatic steatosis. J Viral Hepat 2013; 20: 77-84, PMID: 23301542 DOI: 10.1111/jvh.12035
8. Solis-Herruzo JA, Pérez-Carreras M, Rivas E, Fernández-Vázquez I, Garfia C, Bernardos E, Castellano G, Colina F. Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 2005; 100: 1091-1098, PMID: 15842583 DOI: 10.1111/j.1572-0241.2005.41059.x
9. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-736, PMID: 12198667 DOI: 10.1053/jhep.2002.35064
10. Hézode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004; 11: 455-458, PMID: 15357652 DOI: 10.1111/j. 1365-2893.2004.0052 8.x
11. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-666, PMID: 19665246 DOI: 10.1016/j. jhep.2009.05.016
12. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Bréchot C. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94: 1200-1205, PMID: 9037030
13. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78 (Pt 7): 1527-1531, PMID: 9225025
14. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-115, PMID: 10905593 DOI: 10.1016/S0168-8278(00)80166-X
15. Hourioux C, Patient R, Morin A, Blanchard E, Moreau A, Trassard S, Giraudeau B, Roingeard P. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007; 56: 1302-1308, PMID: 17213339
16. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364, PMID: 11391523
17. Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol 2005; 40: 329-336, PMID: 15868369 DOI: 10.1007/s00535-005-1586-z
18. Masarone M, La Mura V, Bruno S, Gaeta GB, Vecchione R, Carrino F, Moschella F, Torella R, Persico M. Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCVrelated chronic liver disease. J Viral Hepat 2007; 14: 714-720, PMID: 17875006 DOI: 10.1111/j.1365-2893.2007.00861.x
19. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008; 47: 2127-2133, PMID: 18446789 DOI: 10.1002/hep.22269
20. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185-194, PMID: 11818366 DOI: 10.1096/fj. 01-0396com
21. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalphanull mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999; 96: 7473-7478, PMID: 10377439
22. Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, Powell EE, Tilg H. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005; 43: 929-936, PMID: 16139921 DOI: 10.1016/j. jhep.2005.05.030
23. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289, PMID: 8619847 DOI: 10.1006/bbrc. 1996.0587
24. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-40363, PMID: 12878598 DOI: 10.1074/jbc.M300365200
25. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-121, PMID: 15591515 DOI: 10.1136/gut.2003.037010
26. Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 2002; 440: 213-221, PMID: 12007537 DOI: 10.1016/S0014-2999(02)0 1430-9
27. Sheng T, Yang K. Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 2008; 35: 321-326, PMID: 18571119 DOI: 10.1016/S1673-8527(08)60 047-8
28. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochem Biophys Res Commun 2012; 425: 560-564, PMID: 22925674 DOI: 10.1016/j. bbrc. 2012.08.024
29. Abenavoli L. Adiponectin levels in nonalcoholic fatty liver disease. Metabolism 2011; 60: e3, PMID: 21917277 DOI: 10.1016/j.metabol.2011.08.002
30. Lautamäki R, Rönnemaa T, Huupponen R, Lehtimäki T, Iozzo P, Airaksinen KE, Knuuti J, Nuutila P. Low serum adiponectin is associated with high circulating oxidized lowdensity lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 2007; 56: 881-886, PMID: 17570246 DOI: 10.1016/j.metabol.2007.01.018
31. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism 2004; 53: 589-593, PMID: 15131762 DOI: 10.1016/j. metabol.2003.12.008
32. Christou GA, Tellis KC, Elisaf MC, Tselepis AD, Kiortsis DN. High density lipoprotein is positively correlated with the changes in circulating total adiponectin and highmolecular weight adiponectin during dietary and fenofibrate treatment. Hormones (Athens) 2012; 11: 178-188, PMID: 22801564
33. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323: 630-635, PMID: 15369797 DOI: 10.1016/j. bbrc.2004.08.145
34. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769, PMID: 12802337 DOI: 10.1038/nature01705
35. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase. Nat Med 2002; 8: 1288-1295, PMID: 12368907 DOI: 10.1038/nm788
36. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc Cc, Itani SI, Lodish HF, Ruderman NB. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002; 99: 16309-16313, PMID: 12456889 DOI: 10.1073/pnas.222657499
37. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339, PMID: 17268472 DOI: 10.1038/nm1557
38. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-2010, PMID: 11172066 DOI: 10.1073/pnas.98.4.2005
39. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-2468, PMID: 12431986 DOI: 10.1074/jbc.M209033200
40. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792, PMID: 16823476 DOI: 10.1172/JCI29126
41. Liu Q, Gauthier MS, Sun L, Ruderman N, Lodish H. Activation of AMP-activated protein kinase signaling pathway by adiponectin and insulin in mouse adipocytes: requirement of acyl-CoA synthetases FATP1 and Acsl1 and association with an elevation in AMP/ATP ratio. FASEB J 2010; 24: 4229-4239, PMID: 20667975 DOI: 10.1096/fj. 10-159723
42. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 2008; 32 Suppl 7: S13-S18, PMID: 19136982 DOI: 10.1038/ijo.2008.233
43. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005; 54: 3358-3370, PMID: 16306350 DOI: 10.2337/diabetes.54.12.3358
44. Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Probiotics in non-alcoholic fatty liver disease: which and when. Ann Hepatol 2013; 12: 357-363, PMID: 23619251
45. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Macé K, Chou CJ. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008; 22: 2416-2426, PMID: 18326786 DOI: 10.1096/fj.07-102723
46. Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 2010; 53: 606-613, PMID: 20101384 DOI: 10.1007/ s00125-010-1662-7
47. Targher G, Bertolini L, Scala L, Poli F, Zenari L, Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf) 2004; 61: 700-703, PMID: 15579183 DOI: 10.1111/j.1365-2265.2004.02151.x
48. Im JA, Kim SH, Lee JW, Shim JY, Lee HR, Lee DC. Association between hypoadiponectinemia and cardiovascular risk factors in nonobese healthy adults. Metabolism 2006; 55: 1546-1550, PMID: 17046559 DOI: 10.1016/j.metabol.2006.06.027
49. Asano T, Watanabe K, Kubota N, Gunji T, Omata M, Kadowaki T, Ohnishi S. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol 2009; 24: 1669-1676, PMID: 19788607 DOI: 10.1111/ j.1440-1746.2009.06039.x
50. Petit JM, Minello A, Jooste V, Bour JB, Galland F, Duvillard L, Verges B, Olsson NO, Gambert P, Hillon P. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab 2005; 90: 2240-2243, PMID: 15644404 DOI: 10.1210/ jc.2004-1266
51. Liu CJ, Chen PJ, Jeng YM, Huang WL, Yang WS, Lai MY, Kao JH, Chen DS. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005; 43: 235-242, PMID: 15964656 DOI: 10.1016/j.jhep.2005.02.044
52. Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factoralpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006; 24: 1349-1357, PMID: 17059516 DOI: 10.1111/ j.1365-2036.2006.03114.x
53. Zhang L, Sugiyama T, Murabayashi N, Umekawa T, Ma N, Kamimoto Y, Ogawa Y, Sagawa N. The inflammatory changes of adipose tissue in late pregnant mice. J Mol Endocrinol 2011; 47: 157-165, PMID: 21697073 DOI: 10.1530/ JME-11-0030
54. Lira FS, Rosa JC, Cunha CA, Ribeiro EB, do Nascimento CO, Oyama LM, Mota JF. Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1 adipocytes following LPS stimulation. Lipids Health Dis 2011; 10: 37, PMID: 21352586 DOI: 10.1186/1476-511X-10-37
55. Feng B, Jiao P, Nie Y, Kim T, Jun D, van Rooijen N, Yang Z, Xu H. Clodronate liposomes improve metabolic profile and reduce visceral adipose macrophage content in diet-induced obese mice. PLoS One 2011; 6: e24358, PMID: 21931688 DOI: 10.1371/journal.pone.0024358
56. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285: E527-E533, PMID: 12736161]
57. De Maria N, Colantoni A, Fagiuoli S, Liu GJ, Rogers BK, Farinati F, Van Thiel DH, Floyd RA. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med 1996; 21: 291-295, PMID: 8855439 DOI: 10.1016/0891-5849(96)00044-5
58. Wright E, Scism-Bacon JL, Glass LC. Oxidative stress in type diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 2006; 60: 308-314, PMID: 16494646 DOI: 10.1111/ j.1368-5031.2006.00825.x
59. Neuman MG, Benhamou JP, Marcellin P, Valla D, Malkiewicz IM, Katz GG, Trepo C, Bourliere M, Cameron RG, Cohen L, Morgan M, Schmilovitz-Weiss H, Ben-Ari Z. Cytokine--chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 2007; 149: 126-136, PMID: 17320798 DOI: 10.1016/ j.trsl.2006.11.002
60. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE. Structurefunction studies of the adipocyte-secreted hormone Acrp30/ adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085, PMID: 12496257 DOI: 10.1074/jbc.M207198200
61. Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, Podevin P, Conti F, Canva V, Philippe D, Gambiez L, Mathurin P, Paris JC, Schoonjans K, Calmus Y, Pol S, Auwerx J, Desreumaux P. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128: 334-342, PMID: 15685545 DOI: 10.1053/j.gastro.2004.11.016
62. Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293-300, PMID: 12611609 DOI: 10.1530/eje. 0.1480293
63. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 200-206, PMID: 14715850 DOI: 10.1210/jc.2003-031315
64. Ashour E, Samy N, Sayed M, Imam A. The relationship between serum adiponectin and steatosis in patients with chronic hepatitis C genotype-4. Clin Lab 2010; 56: 103-110, PMID: 20476641
65. Corbetta S, Redaelli A, Pozzi M, Bovo G, Ratti L, Redaelli E, Pellegrini C, Beck-Peccoz P, Spada A. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection. Eur J Clin Invest 2011; 41: 898-905, PMID: 21539538 DOI: 10.1111/j.1365-2362.2011.02498.x
66. Tiftikci A, Atug O, Yilmaz Y, Eren F, Ozdemir FT, Yapali S, Ozdogan O, Celikel CA, Imeryuz N, Tozun N. Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. Arch Med Res 2009; 40: 294-298, PMID: 19608019 DOI: 10.1016/j.arcmed.2009.04.008
67. Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y, Itoh M. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism 2008; 57: 268-273, PMID: 18191059 DOI: 10.1016/j.metabol.2007.09.011
68. Aksõz K, Unsal B, Kirci A, Alper E, Buyraç Z, Aslan F, Cekiç C, Cengiz O, Ozcan Ari F, Akpinar Z. The relationship between chronic HCV infection and the level of plasma adiponectin. Turk J Gastroenterol 2008; 19: 254-257, PMID: 19119485
69. Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani L, Motta BM, Canavesi E, Fracanzani AL, Mozzi E, Roviaro G, Magni P, Fargion S. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol 2012; 12: 111, PMID: 22898488 DOI: 10.1186/1471-230X-12-111
70. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL,Rametta R, Colombo M, Fargion S. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011; 53: 791-799, PMID: 21319195 DOI: 10.1002/hep.24123
71. Nakamura M, Kanda T, Nakamoto S, Miyamura T, Jiang X, Wu S, Yokosuka O. No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. PLoS One 2013; 8: e81312, PMID: 24349054 DOI: 10.1371/journal.pone.0081312.
72. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-12771, PMID: 10535997 DOI: 10.1073/ pnas.96.22.12766
73. Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 2006; 291: E1100-E1105, PMID: 16803857 DOI: 10.1152/ ajpendo.00187.2006
74. Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 2006; 290: E42-E46, PMID: 16118250 DOI: 10.1152/ajpendo.00240.2005
75. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354-1361, PMID: 9502777 DOI: 10.1172/JCI1235
76. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fatderived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-1663, PMID: 12829629 DOI: 10.2337/diabetes.52.7.1655
77. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the reninangiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81, PMID: 12796280 DOI: 10.1161/01.HYP.0000078490.59735.6E
78. Xu A, Wang H, Hoo RL, Sweeney G, Vanhoutte PM, Wang Y, Wu D, Chu W, Qin G, Lam KS. Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice. Endocrinology 2009; 150: 625-633, PMID: 18927219 DOI: 10.1210/en.2008-0999
79. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009; 30: 234-239, PMID: 19359049 DOI: 10.1016/j.tips.2009.02.004
80. Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U, Gerken G, Gieseler RK, Dienes HP, Canbay A. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J Hepatol 2009; 50: 140-149, PMID: 19019483 DOI: 10.1016/j.jhep.2008.08.023
81. Palmer C, Hampartzoumian T, Lloyd A, Zekry A. A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology 2008; 48: 374-384, PMID: 18666256 DOI: 10.1002/hep.22387]